SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma

BACKGROUND: In preclinical Ewing sarcoma (ES) models, poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors were identified as a potential therapeutic strategy with synergy in combination with cytotoxic agents. This study evaluated the safety and dosing of the PARP1/2 inhibitor niraparib (...

Descripción completa

Detalles Bibliográficos
Autores principales: Chugh, Rashmi, Ballman, Karla V., Helman, Lee J., Patel, Shreyaskumar, Whelan, Jeremy S., Widemann, Brigitte, Lu, Yao, Hawkins, Douglas S., Mascarenhas, Leo, Glod, John W., Ji, Jiuping, Zhang, Yiping, Reinke, Denise, Strauss, Sandra J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246769/
https://www.ncbi.nlm.nih.gov/pubmed/33289920
http://dx.doi.org/10.1002/cncr.33349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246769/
https://www.ncbi.nlm.nih.gov/pubmed/33289920
http://dx.doi.org/10.1002/cncr.33349

Ejemplares similares